Group 1: Company Overview - The main product of Shanxi Zhendong Pharmaceutical Co., Ltd. is primarily for internal use, with a small portion sold externally, mainly through direct contact with manufacturers, rather than through the herbal market [2] - The company is exploring the U.S. market for its traditional Chinese medicine products, as there are approximately 6,000 TCM research institutions in the U.S., with around 4,000 requiring imports of Chinese extracts [2] Group 2: Product Development and Sales - The company aims to diversify its product line beyond its main product, Yanshu, which has limited usage; it plans to increase investment in secondary products like Bicalutamide and Pemetrexed Disodium to drive growth [3] - Currently, the company has over 1,000 sales personnel, focusing on self-sales of core products [3] Group 3: Mergers and Acquisitions - The company is actively seeking suitable merger and acquisition targets, having established a new investment team to identify quality opportunities [3] Group 4: International Collaboration - The company has established a research office in collaboration with the National Academy of Traditional Chinese Medicine at the U.S. National Cancer Institute to promote TCM in cancer treatment [4] - It is a member of the International TCM Cancer Treatment Alliance, aiming to accelerate research and promotion of traditional Chinese medicine [4] - The company signed a cooperation agreement for EU registration of its compound TCM products, marking its entry into the European market [4] Group 5: Research Achievements - Recent research by the company, in collaboration with the Guang'anmen Hospital of the China Academy of Chinese Medical Sciences and the U.S. National Cancer Institute, has demonstrated the efficacy of its compound Ku Shen injection in treating cancer pain, published in a prominent international oncology journal [5] - The Yanshu compound Ku Shen injection is effective in inhibiting cancer pain, bleeding, and tumor growth, and is widely used in cancer treatment [5]

Group 1: Major Asset Restructuring - The purpose of the major asset restructuring is to enhance the company's core competitiveness by acquiring products with strong market presence, such as Calcium D3 tablets and granules, which have high market recognition and share [3] - The acquisition will allow the company to quickly gain access to competitive products, diversify its product range, and reduce operational risks [3] - The integration of Calcium D3 products with existing offerings aims to boost sales of other OTC products, leveraging the growing health product market [3] Group 2: Impact on Business Strategy - Post-restructuring, the company will have a richer product line and gain access to competitive pharmaceutical varieties, facilitating rapid growth [3] - The acquired company, Kangyuan Pharmaceutical, will become a wholly-owned subsidiary, benefiting from improved governance and management through capital market support [4] - The transaction aligns with both parties' strategic goals, maximizing profits and achieving strategic synergy [4] Group 3: Dividend and Profit Distribution - The board will consider investors' reasonable demands for returns, discussing profit distribution plans, including stock dividend proposals, based on business development and financial needs [4] - Any progress on profit distribution will be announced in accordance with regulations [4] Group 4: Sales and Market Performance - The sales volume of the company's main product, Yanshu Injection, is expected to remain stable this year, with ongoing clinical trials for new formulations [5] - The company aims to strengthen its sales team as a key strategy for future growth, addressing past mismatches in brand, capacity, and marketing [6] - The company has implemented significant reforms in its marketing structure, relocating its marketing team to Beijing to enhance talent acquisition and information flow [6] Group 5: Future Development Plans - The company plans to continue investing in traditional Chinese medicine and improve its supply chain to support farmers, with significant benefits already observed [5] - The focus remains on developing traditional Chinese medicine oncology drugs, with a clear strategy for future research and development [6]

Group 1: Company Strategy and Development - The company is not undergoing a transformation but rather a significant change since its strategic direction has been clear since 2003, focusing on traditional Chinese medicine, oncology drugs, and the major product series of Sophora flavescens [2][3] - The company has acquired several firms, including Tai Sheng Pharmaceutical, Kai Yuan Pharmaceutical, and An Te Biological Pharmaceutical, leading to a diversified development strategy [3] - The company aims to enhance brand awareness and sales through mergers and acquisitions, particularly in the OTC drug market, leveraging the brand of Kangyuan Pharmaceutical's calcium D3 preparation, which is a leading brand in the calcium supplement market [3][4] Group 2: Market Challenges and Responses - Current medical insurance policies significantly impact high-priced major products, but low-priced minor products remain less affected; the company's flagship product, Yan Shu, still has considerable potential for development [3][4] - The company will not diversify further despite changes in national medical policies; it will focus on existing products and enhance the quality of its offerings [4][5] Group 3: Research and Development Focus - The company is concentrating on oncology drugs, which are a global challenge, while also addressing major diseases in China, such as hepatitis B and diabetes [5][6] - Recent developments include obtaining clinical approval for a new drug, Laloheza lipid microsphere injection, which has stronger anti-tumor activity than existing treatments [5][6] Group 4: Sales and Market Positioning - The company does not plan to significantly expand its sales team but will enhance the academic capabilities and overall quality of its personnel; in 2016, the focus will be on structural adjustments and reducing sales expenses [5][6] - The acquisition of Kangyuan Pharmaceutical was aimed at improving the company's market value management and leveraging its sales advantages to boost the sales and profits of calcium preparations [5][6]

证券代码：300158 证券简称：振东制药 编号：2 | --- | --- | --- | |-----------------------|-------------------------|------------------------------------------------------| | | | | | | | □特定对象调研 □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 | □ | 新闻发布会 √路演活动 | | 类别 | □现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | 参与单位名称及 | 广大投资者 | | | 人员姓名 | | | | 时间 | 2016 年 1 月 29 | 日 | | 地点 | 上海世纪大道 | 1568 号中建大厦 22F 中信证券 04 会议室 | | 上市公司接待人 员姓名 | 李安平 宁潞宏 | 马士锋 徐根旺 | | 投资者关系活动 | 1 . | 复方苦参注射液现在能否完全满足企业生产需求？ | | 主要内容介绍 | | 答：现在完全能满足生产需求，岩舒是我们的独家产品，有 | | | G ...

证券代码：300158 证券简称：振东制药 编号：2020-001 山西振东制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------|--------------------------------| | | | | | | □ | 特定对象调研 □分析师会议 | | | □ 媒体采访 □ | 业绩说明会 | | 投资者关系活动 | □ 新闻发布会 √路演活动 | | | 类别 | □ 现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | 参与单位名称及 | 机会宝 范莉莉 | | | 人员姓名 | 机会宝 客服 | | | | 机会宝 雷晨昊 | | | | 机会宝 彭博 | | | | 机会宝 王冰清 | | | | 机会宝 王戊军 | | | | 机会宝 吴琪 | | | | 机会宝 肖佳楣 | | | | 机会宝 徐姗姗 | | | | 机会宝 益正徐翾 | | | | 机会宝 张佳 | | | | 中银基金 王帅 | | | | 中投证券 袁超 | | | --- | --- ...

证券代码：300158 证券简称：振东制药 山西振东制药股份有限公司投资者关系活动记录表 编号：2021-001 | --- | --- | --- | --- | --- | |----------------|--------------|--------------------------------|-------|-------| | | | | | | | | 特定对象调研 | 分析师会议 | | | | | 媒体采访 | 业绩说明会 | | | | 投资者关系活动 | 新闻发布会 | 路演活动 | | | | 类别 | 现场参观 | | | | | | | 其他（请文字说明其他活动内容） | | | | | 贵源投资 | 赖正健 | | | | | 贵源投资 | 纵华雷 | | | | | 巴富罗投资 | 浩 | | | | | 移 民 局 | 费维俊 | | | | | 中银证券 | 魏泽辉 | | | | | 中银证券 | 徐东栋 | | | | 参与单位名称及 | 承风金平 | 承 | | | | 人员姓名 | 证券日报 | 陈慕鸿 | | | | | 证券日报 | 赵瑞东 | | | | ...

证券代码：300158 证券简称：振东制药 山西振东制药股份有限公司投资者关系活动记录表 编号：2021-002 | --- | --- | --- | --- | --- | |----------------|---------------------|--------------|--------------------------------|-------| | | | | | | | | | 特定对象调研 | 分析师会议 | | | | 媒体采访 | | 业绩说明会 | | | 投资者关系活动 | | 新闻发布会 | 路演活动 | | | 类别 | | | | | | | 现场参观 | | | | | | | | 其他（请文字说明其他活动内容） | | | | 浦银安盛： | | | | | | 研究总监 | | 蒋佳良 | | | 参与单位名称及 | 基金经理 基金经理 | 赵 | 胡攸乔 宁 | | | 人员姓名 | 基金经理 | | 杨富麟 | | | | 研 究 员 | | 杨达伟 | | | | 研 究 员 | 徐 | 博 | | | | 研 究 员 | 沈 | 瑞 | | | 时间 | ...

证券代码：300158 证券简称：振东制药 山西振东制药股份有限公司投资者关系活动记录表 编号：2021-006 | --- | --- | --- | --- | --- | |----------------|--------------|--------------------------------|-------|-------| | | | | | | | | 特定对象调研 | 分析师会议 | | | | | 媒体采访 | 业绩说明会 | | | | 投资者关系活动 | 新闻发布会 | 路演活动 | | | | 类别 | 现场参观 | | | | | | | 其他（请文字说明其他活动内容） | | | | | 华泰证券 | 岳梅梅 | | | | | 华泰证券 | 李奕玮 | | | | | 华泰证券 | 张光耀 | | | | | 泾溪投资 | 宇 | | | | | 中信资管 | 康 | | | | | 北信瑞丰 | 庞文杰 | | | | | 嘉实基金 | 朱子君 | | | | | 嘉实基金 | 歌 | | | | | 嘉实基金 | 肖琪严 | | | | 参与单位名称及 | 嘉实基金 | ...

山西振东制药股份有限公司 2022 年第三季度报告 证券代码：300158 证券简称：振东制药 公告编号：2022-063 山西振东制药股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 山西振东制药股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|-------------------------|--------- ...

山西振东制药股份有限公司 2022 年半年度报告全文 山西振东制药股份有限公司 2022 年半年度报告 2022-046 【2022 年 8 月】 1 山西振东制药股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人李安平、主管会计工作负责人刘长禄及会计机构负责人(会计 主管人员)刘长禄声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司在本报告第三节"管理层讨论与分析"中"十、公司面临的风险和应 对措施"部分，详细描述了公司经营中可能存在的风险，敬请投资者关注相 关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 山西振东制药股份有限公司 2022 年半年度报告全文 目录 | --- | --- | |------------------------------------------------------------------------------- ...